Bridget E. Bunner

Array ( [id] => 13929653 [patent_doc_number] => 20190048342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => CROSS-REGULATION OF TYPE I INTERFERON SIGNALING PATHWAYS [patent_app_type] => utility [patent_app_number] => 16/075661 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14360207 [patent_doc_number] => 10301391 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-28 [patent_title] => BCMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 15/422619 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 19 [patent_no_of_words] => 45611 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11879653 [patent_doc_number] => 09750808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-05 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 15/418460 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13764 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670038 [patent_doc_number] => 20170158759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/418469 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13552 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844607 [patent_doc_number] => 09732152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 15/418465 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13757 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627298 [patent_doc_number] => 20170137487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES' [patent_app_type] => utility [patent_app_number] => 15/411649 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 31756 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12259301 [patent_doc_number] => 20180078496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT' [patent_app_type] => utility [patent_app_number] => 15/409377 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15293 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15409377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729318 [patent_doc_number] => 20170190761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR' [patent_app_type] => utility [patent_app_number] => 15/404749 [patent_app_country] => US [patent_app_date] => 2017-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 46725 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15404749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690912 [patent_doc_number] => 20170166627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY' [patent_app_type] => utility [patent_app_number] => 15/385222 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 28693 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11542668 [patent_doc_number] => 20170096493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'Anti Human Notch4 Antibody' [patent_app_type] => utility [patent_app_number] => 15/382821 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16953 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15382821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12999967 [patent_doc_number] => 10023641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => Anti-TIE2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/373903 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14288 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448614 [patent_doc_number] => 09982058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Anti-JAG1 antibody compositions and methods for treatment of hepatic cancers [patent_app_type] => utility [patent_app_number] => 15/373275 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 71 [patent_no_of_words] => 33191 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15373275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866200 [patent_doc_number] => 20170233486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'POLYNUCLEOTIDES ENCODING ANTI-NOTCH1 NRR ANTIBODY POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/359098 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 58367 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15359098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851726 [patent_doc_number] => 20170226218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'Method for In Vivo Expansion of T Regulatory Cells' [patent_app_type] => utility [patent_app_number] => 15/357891 [patent_app_country] => US [patent_app_date] => 2016-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 20588 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15357891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471259 [patent_doc_number] => 20170058041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'Toll-Like Receptor 3 Antagonists' [patent_app_type] => utility [patent_app_number] => 15/345860 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 34869 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15345860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641286 [patent_doc_number] => 20180105593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR [patent_app_type] => utility [patent_app_number] => 15/339778 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604079 [patent_doc_number] => 20170121380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Composition for Preventing or Treating Fatty Liver or Insulin Resistance Syndrome Including Extracellular Domain of Delta-Like 1 Homolog' [patent_app_type] => utility [patent_app_number] => 15/337208 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8867 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15337208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690916 [patent_doc_number] => 20170166632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent' [patent_app_type] => utility [patent_app_number] => 15/336272 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13812 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15336272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743958 [patent_doc_number] => 20170198031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/298527 [patent_app_country] => US [patent_app_date] => 2016-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 54930 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15298527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714906 [patent_doc_number] => 20170183405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/291334 [patent_app_country] => US [patent_app_date] => 2016-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 34036 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15291334 [rel_patent_id] =>[rel_patent_doc_number] =>)